These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 9387958)
1. Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients. Bargon J; Viel K; Dauletbaev N; Wiewrodt R; Buhl R Eur Respir J; 1997 Oct; 10(10):2307-11. PubMed ID: 9387958 [TBL] [Abstract][Full Text] [Related]
2. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Appleton S; Smith B; Veale A; Bara A Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594 [TBL] [Abstract][Full Text] [Related]
3. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. van der Woude HJ; Winter TH; Aalbers R Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351 [TBL] [Abstract][Full Text] [Related]
4. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853 [TBL] [Abstract][Full Text] [Related]
5. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. Lazarus SC; Boushey HA; Fahy JV; Chinchilli VM; Lemanske RF; Sorkness CA; Kraft M; Fish JE; Peters SP; Craig T; Drazen JM; Ford JG; Israel E; Martin RJ; Mauger EA; Nachman SA; Spahn JD; Szefler SJ; JAMA; 2001 May 23-30; 285(20):2583-93. PubMed ID: 11368732 [TBL] [Abstract][Full Text] [Related]
6. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Hordvik NL; Sammut PH; Judy CG; Colombo JL Pediatr Pulmonol; 1999 Jan; 27(1):43-53. PubMed ID: 10023791 [TBL] [Abstract][Full Text] [Related]
7. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Boulet LP; Cartier A; Milot J; Côté J; Malo JL; Laviolette M Eur Respir J; 1998 May; 11(5):1091-7. PubMed ID: 9648961 [TBL] [Abstract][Full Text] [Related]
8. The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma. Dal Negro RW; Micheletto C; Tognella S; Trevisan F; Guerriero M Eur Ann Allergy Clin Immunol; 2006 May; 38(5):153-7. PubMed ID: 17058847 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Hordvik NL; Sammut PH; Judy CG; Colombo JL Pediatr Pulmonol; 2002 Oct; 34(4):287-96. PubMed ID: 12205570 [TBL] [Abstract][Full Text] [Related]
10. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371 [TBL] [Abstract][Full Text] [Related]
11. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group. Kemp JP; Cook DA; Incaudo GA; Corren J; Kalberg C; Emmett A; Cox FM; Rickard K J Allergy Clin Immunol; 1998 Feb; 101(2 Pt 1):188-95. PubMed ID: 9500751 [TBL] [Abstract][Full Text] [Related]
12. Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Salvatore D; D'Andria M Pediatr Pulmonol; 2002 Jul; 34(1):11-5. PubMed ID: 12112791 [TBL] [Abstract][Full Text] [Related]
13. Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo. Langley SJ; Masterson CM; Batty EP; Woodcock A Eur Respir J; 1998 May; 11(5):1081-5. PubMed ID: 9648959 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Nightingale JA; Rogers DF; Barnes PJ Chest; 2002 May; 121(5):1401-6. PubMed ID: 12006420 [TBL] [Abstract][Full Text] [Related]
16. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. König P; Gayer D; Barbero GJ; Shaffer J Pediatr Pulmonol; 1995 Oct; 20(4):205-14. PubMed ID: 8606849 [TBL] [Abstract][Full Text] [Related]
17. Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Dahl R; Earnshaw JS; Palmer JB Eur Respir J; 1991 Nov; 4(10):1178-84. PubMed ID: 1687131 [TBL] [Abstract][Full Text] [Related]
18. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Rosenthal RR; Busse WW; Kemp JP; Baker JW; Kalberg C; Emmett A; Rickard KA Chest; 1999 Sep; 116(3):595-602. PubMed ID: 10492259 [TBL] [Abstract][Full Text] [Related]
19. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. Wong AG; O'Shaughnessy AD; Walker CM; Sears MR Eur Respir J; 1997 Feb; 10(2):330-6. PubMed ID: 9042628 [TBL] [Abstract][Full Text] [Related]
20. Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Tsagaraki V; Amfilochiou A; Markantonis SL Int J Clin Pract; 2006 Apr; 60(4):415-21. PubMed ID: 16620353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]